Group 1 - Gan Li Pharmaceutical has announced a collaboration with Crystal Holdings for AI peptide innovation drug development in the metabolic disease field, marking a strategic upgrade for the company [1] - The collaboration aims to combine Gan Li's deep understanding of patient needs and research challenges with Crystal Holdings' advanced AI computing capabilities to explore more efficient and intelligent research pathways [1] - The agreement will utilize Crystal Holdings' proprietary AI peptide research platform, PepiX, to accelerate the discovery and development of new peptide drugs targeting unmet treatment needs in metabolic diseases [1] Group 2 - The AI healthcare market is projected to reach approximately $11.66 billion in 2024, with a compound annual growth rate of 25.83% from 2024 to 2029 [2] - Despite rapid growth, the industry faces challenges such as the contradiction between the sensitivity of medical data and the need for sharing, algorithm transparency issues, and a shortage of interdisciplinary talent [2] - Ensuring the reliability and safety of AI systems is a critical issue in the development of the industry [2]

Group 1 - The core viewpoint of the article is that Gan Li Pharmaceutical has entered into a research collaboration with Jingtai Technology to develop innovative AI peptide drugs for metabolic diseases [1] - The agreement allows Gan Li Pharmaceutical to utilize Jingtai Technology's proprietary AI peptide research platform, PepiX™, to focus on unmet therapeutic needs in the field of metabolic diseases [1] - The collaboration aims to accelerate the discovery and development process of new peptide-based innovative drugs [1]